NewTimeSpace News: AUNTEA JENNY(02589.HK) voluntarily announced that six shareholders including Suzhou Yizhong have voluntarily undertaken to cap their share reductions during the period from August 7, 2026 to November 7, 2026, with an aggregate cap of no more than 3,684,228 shares (approximately 3.50% of total issued shares); five other shareholders' existing undertakings not to reduce their shareholdings until November 7 remain unchanged.
NewTimeSpace News: RUIHE DATA(03680.HK) announced that its indirect wholly-owned subsidiary Ruihe Data (Shenzhen) has entered into a partnership agreement with Youshi Financial Holding and Hainan Baoshu to establish a venture capital fund with aggregate committed capital of RMB 100 million (Ruihe Data contributing RMB 11.9 million, or 11.90%), targeting emerging pillar and future industries such as new energy, the low-altitude economy, quantum technology and embodied intelligence; as Youshi Financial Holding is 39.92% owned by non-executive director Mr. Wu Kezhong, the establishment constitutes a connected transaction exempt from independent shareholders' approval.
NewTimeSpace News: GRANDPHARMA(00512.HK) announced that GPN01530-2, its self-developed innovative RDC for solid tumor diagnosis, has been granted FDA Fast Track Designation; the drug is a small-molecule FAP-targeting agent that had previously been approved for Phase I/II clinical studies; the global radiopharmaceutical market reached USD 9.7 billion in 2024 and is projected to reach USD 57.3 billion by 2035, while the Group has reserved 16 innovative products in its nuclear medicine segment with six RDCs approved for registered clinical studies.
NewTimeSpace News: WUXI APPTEC (02359.HK) announced that the US District Court for the District of Columbia granted the Company's motion for a preliminary injunction on August 7, 2026, shielding the Company from immediate adverse effects of the DoD's 1260H designation during the judicial proceedings; the Company filed the lawsuit on June 11, 2026, the injunction motion on June 29, 2026, and the hearing was held on July 22, 2026, with the business operating normally.
NewTimeSpace News: LUZHU BIOTECH-B (02480.HK) announced that the Phase III results of its core product LZ901 in China were published in Nature Communications: overall vaccine efficacy of 91.6% within one year (95% CI: 86.3%–95.3%), 92.1% against laboratory-confirmed cases and 95.9% against postherpetic neuralgia, with 26,039 subjects enrolled and 25,577 vaccinated; the BLA is currently under review by the NMPA.
The Hang Seng Index fell 0.84% cumulatively this week, with southbound capital recording a net inflow of approximately HKD 9.9 billion for the full week. The innovative drug sector led the week, catalyzed by BEONE MEDICINES' net profit surging 627% and REMEGEN's first large-scale profitability, with related ETFs sweeping the gainers board; MINIMAX was formally admitted to HK Stock Connect on 6 August, accumulating approximately 28.6% over two days, with Z.AI climbing in tandem and the twin large-model titans performing prominently; CPO and solar sectors also delivered strong performances. In terms of connectivity, the regulators released signals on including REITs in the Shanghai-Shenzhen-Hong Kong Stock Connect, the second phase of HKEX's minimum spread reduction took effect, and a total of four targets including MINIMAX and NEXCHIP were admitted this week.
This week, HK newly listed stocks saw more gainers than losers, with NASN TECH up 64% on its debut day and AI concept stocks such as MINIMAX-W and VGT up over 38%; JIANGXI BIO fell 37%. The seven stocks with lock-up expiries performed mildly, with declines such as MUYUAN and EASTROC all within 11%, and the lock-up expiry impact was clearly weaker than last week. QIYUNSHAN FOOD rose 1,147% cumulatively to overtake DEEPZERO at the top, while ZG GROUP-W returned to the biggest drop below its IPO price. Z.AI returned to the top of liquidity with average daily turnover of nearly HKD 7 billion. Next week, AB&B BIO-TECH-B and INNOGEN-B will unlock more than 260 million shares.
NewTimeSpace News: August 07, 2026, MIN FU INTL(08511.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 52.89 million, increased by 90.04% YoY
NewTimeSpace News: SUNMI TECH-W (06810.HK) voluntarily announced that cornerstone investor XINWUTANG CO., LIMITED has voluntarily extended the six-month lock-up period by five months to March 28, 2027 (originally ending October 28, 2026); the cornerstone investor holds 9,945,700 H shares, representing approximately 3.33% of issued H shares and approximately 2.47% of total share capital.
NewTimeSpace News: CA CULTURAL(01566.HK) announced that its independent forensic investigation has been completed and adopted by the Board, with no evidence of fraud or misappropriation by directors or management; the investigation covered 20 events including the consultancy advance payment (HKD 50 million), financial support from Mr. Chong Heung Chung (HKD 81,954,820.82), the ACCP Global subscription default (HKD 215 million) and theme park advance payments (approximately HKD 315 million); no reasonable regulatory concerns over management integrity were identified; the ICAC has concluded its investigation and trading remains suspended.
NewTimeSpace News: JLMAG (06680.HK) voluntarily announced that, as the conditions precedent to the subscription had not been satisfied, the Company terminated the subscription by its wholly-owned subsidiary JL MAG HK Technology for the equity of Australian listed rare earth company Hastings Technology Metals Limited (originally planned at AUD 0.36 per share for 19.647 million shares, with an aggregate amount of approximately AUD 7.07 million); no payment has been made and the termination will not have a material adverse impact.
NewTimeSpace News: Chifeng Gold (06693.HK) announced in an inside information disclosure that, in response to national policy requirements for rare earth resource development, Chijin Xiawu (51%-owned by the Company) has decided to suspend operation of the Mengkang rare earth project in Laos; the project recorded a net loss attributable to the Company of RMB 54.06 million in 2025 (1.75% of the absolute value of consolidated net profit attributable to the parent), and a net profit of RMB 0.37 million in the first quarter of 2026 (0.04%), with the suspension expected to have a relatively small impact on overall operating results.
NewTimeSpace News: Lingbao Gold (03330.HK) announced in an inside information disclosure that the overall exploration of Hababe Huatai in Xinjiang achieved major phased progress, with contained gold metal content (mineral resources) rising to 53.94 tonnes as of June 30, 2026 from 13.20 tonnes at the end of 2025 (ore of 42.43 million tonnes at a grade of 1.27 g/t), prepared by SRK in accordance with the JORC Code; the Company plans to expand depth and capacity leveraging existing facilities and accelerate the conversion from exploration to mining.
NewTimeSpace News: Xunce (03317.HK) announced that the Company has signed a strategic cooperation MOU with Tianhe Computing Power, a wholly-owned subsidiary of Trina Solar, to cooperate on energy vertical large language models, data assetization, power-computing coordination and Token factory commercialization, jointly building energy data infrastructure, creating green computing application scenarios and exploring energy Token factory business models; the MOU does not yet constitute a specific business contract.
NewTimeSpace News: GME Group (08188.HK) voluntarily announced that its indirect wholly-owned subsidiary, GME Engineering, has been awarded three infrastructure works contracts for Hung Shui Kiu under the Northern Metropolis (approximately HKD 38 million) and four infrastructure works contracts for SKYTOPIA (approximately HKD 157 million), with an aggregate contract value of approximately HKD 195 million; the works have commenced and are expected to be completed within approximately three months to two years.
NewTimeSpace News: SBP GROUP (01177.HK) announced that benmelstobart (Andevi) in combination with chemotherapy and sequentially with anlotinib (Focovi), independently developed by subsidiary Chia Tai Tianqing, has been approved by the NMPA for first-line treatment of locally advanced or metastatic squamous NSCLC, marking the 12th indication for anlotinib and the 6th for benmelstobart; the Phase III trial ETER700 showed PFS of 11.20 months versus 8.28 months (HR 0.68) and an OS HR of 0.75, making it the world's first head-to-head study demonstrating superiority over the standard immunotherapy-plus-chemotherapy regimen in first-line sq-NSCLC.
